Introduction
Malignant mesothelioma (MM) has recently attracted the attention of the media because of its relationship with professional and environmental exposure to asbestos. This tumour of the pleura is a disease which has emerged in significant numbers of patients during the last 30 years in the industrialized countries, and its increasing incidence makes it of socio-economical interest.
The histological description of MM was first published by E. Wagner in 1870 [1] and later by Klemperer and Rabin [2] . A literature review of pathological cases of lung diseases before 1940 identified 41 out of 46,000 autopsies as possible MM [3] . In this review they mentioned a report from 1767 by Lieutaud who was the first to describe two possible cases of MM in an autopsy study. Since then a number of case reports [4] [5] [6] were published in which a relationship with asbestos exposure was considered important but it was the report of J. C. Wagner in 1960 which identified a clear relationship between exposure to crocidolite mining and the development of MM [7] . From that moment the association between asbestos exposure and MM was accepted and a beginning was made to abandon the production and processing of asbestos material.
Epidemiology
Mesothelioma death rate registration has been more accurate since the publication of Wagner in 1960 and a report of the IUCC on the recommendation of the working group on asbestos and cancer in 1965 [7, 8] . Registration in the United States and Canada on the incidence of MM revealed a gradual increase in incidence in both countries [9] [10] [11] . Over the last 40 years the male: female ratio has changed from 1:1 to 4:1 and it is expected that the incidence of MM will continue to rise till approximately 2020 [11, 12] . The incidence for mesothelioma in autopsy series varies from 0.02% to 0.7% according to the level of (industry related) asbestos exposure [13] . The highest incidences are found in shipyard and construction workers, asbestos miners and manufacturers, in heating trade and insulation workers [14] . The lifetime risk for the male population born before 1953 is calculated to be 1%-1.3% with a sharp decrease for those born later [11] . It must be emphasized that the uncertainty with regard to the diagnosis and the occurrence at old age may lead to an underestimation of the real incidence of the disease.
Asbestos related mesothelioma
The long interval between exposure of asbestos and development of mesothelioma has been the reason for the relatively late discovery of the cause. Extensive research revealed a latency period of 30 to 45 years in most cases.
Asbestos minerals can be divided in different types of fibers, each with specific properties. The carcinogenicity differs between the different types of asbestos and is dependent of their physical properties. They can be divided in the serpentines (chrysotile the so called 'white asbestos' and anthophyllite) and the amphiboles (crocidolite the so called 'blue asbestos', amosite the so-called 'brown asbestos' and tremolite). The carcinogenicity appears to be related to the length-to-diameter ratio of asbestos fibers; fibers with the highest ratio being the most carcinogenic. In general the amphiboles have the highest ratio and epidemiologic data confirms their malignant potential [13] . The serpentines are curly and can be broken down easily and removed by the lymphatic system. Despite many data obtained so far, the discussion as to whether chrysotile itself is able to induce mesothelioma is still ongoing. Smith and Wright [15] state in their review, that there is ample evidence that persons exposed directly to chrysotile by mining and indirectly by cleaning the clothes of chrysotile miners have a high risk of developing mesothelioma [16] . Even minimal exposure to mineral fibers as in households could also account for the development of mesothelioma [17, 18] . Further evidence is found in animal studies in which pure chrysotile, injected intra-pleurally was able to induce mesothelioma. The linking of the amphiboles to the development of mesothelioma is much more widely accepted [7, 19] . Churg [20] analyzed the cases of chrysotile induced mesothelioma and found that in 51 of the 53 cases a contamination with one of the amphiboles was found. The amphiboles appear to be 15 times more potent than chrysotile in the development of mesothelioma when data from autopsy studies are used. A mixed form of the asbestos fibers is estimated to be five times more dangerous than pure chrysotile [21] .
Since the introduction of asbestos, its mining and processing, the mean age of patients with MM has increased and approximately 70% of the patients are over 50 years of age. Mesothelioma is extremely rare in childhood [22, 23] .
Non asbestos related induction of mesothelioma
In 70% to 87% of cases of MM an exposure to asbestos can be found [24, 25] . Therefore it is possible that inducers of mesothelioma in humans and animals other than asbestos exist. Most reports describe the development of peritoneal mesothelioma after irradiation for seminoma of the testis [26, 27] , irradiation of the cervix [28] or after administration of thorium dioxide, a radiographic medium [29, 30] . Only two cases with pleural mesothelioma have been reported after irradiation [31, 32] .
Much attention has been given to the epidemic of mesothelioma in the Anatolian region in Turkey where zeolite (respirable erionite) was identified as the only possible causative agent, in the absence of asbestos fibers [33] [34] [35] . The analysis of lung tissue of two patients showed ferruginous bodies surrounding zeolite fibers [36] . In other Turkish areas, however, zeolite was also found but without any increase in the incidence of mesotheliomas [37] .
The use of iatrogenic pneumothorax as in the treatment of tuberculoses has led to the occurrence of a few cases of mesothelioma after many years. There is probably a relationship between chronic irritation and/or inflammation induced in the pleura and the development of MM [38] . Non asbestos fibers like mineral fibers (including glass fibers) have been shown to be able to induce mesotheliomas in animals [39, 40] .
Organic chemicals like polyurethane, polysilicone, ethylene oxide, N-methyl-N-nitrosurethane diethyl stilbestrol and mineral oils have been shown to be able to induce mesotheliomas in rodents. An interesting review on this subject has been published by Peterson [41] .
Pathology of malignant mesothelioma
In the initial stage of MM, the mesothelial tumour cells proliferate and form small nodules or plaques which will eventually coalesce [42, 43] . Pleural effusions occur, frequently followed by obliteration of the pleural space resulting in constriction of the entire lung. Plaques of tumour are mostly observed in the dorsal sinuses. The tumour has a tendency to invade soft tissues of the chest wall and in later stages growth into the lung parenchyma is observed. Malignant mesothelioma is notorious for the invasion of needle tracts and its growth pattern along the interlobular septae. In advanced stages invasion of ribs and vital structures like large vessels, esophagus and heart may occur. Growth through the diaphragmatic hiatus or direct invasion of the diaphragm can lead to peritoneal extension or invasion of the contralateral pleural space.
Although it is generally thought that MM is a localized disease, metastases are observed, in approximately 30% of patients, to the mediastinal lymph nodes [44] and to various parts of the body in end stage disease.
Histological examination of 819 cases revealed three different entities of MM [13] . In 50% the epithelial type, in 34% the mixed type and in 16% the sarcomatous type was observed. In the epithelial type of MM, the cytoplasm is densely eosinophilic with well defined borders. Areas of loose fibrous tissue can occur interspersed with (sometimes) thick bundles of collagen. The growth pattern can be tubular, papillary or microcystic. In the sarcomatous type, spindle shaped cells predominate and the stroma is variable and resembles that of the epithelial type. In the mixed type both entities are observed and their appearance seems to be related to the number and size of the biopsies obtained for diagnosis [45] .
Other serous linings can give rise to MM, e.g., the peritoneum, the tunica vaginalis testis and, rarely, the pericardium [46] . The occurrence in children of MM has been reviewed by Talerman [47] . Although the diagnosis was not always clear, the majority of cases occurred in the pleura but six out of nine female cases had a peritoneal MM [48] .
Differentiating between MM and other forms of cancer (especially adenocarcinoma) is often difficult. Analysis of the histochemical profile by using a series of staining methods (PAS-D, Vimentine, Hyaluronidase), the use of immunohistochemistry (CEA, Keratines) and electron microscopy can facilitate the making of the diagnosis [49, 50] . CEA is especially useful since this stains positive with the majority of adenocarcinomas and in < 5% of MM. The intermediate keratin filaments stain more positive in MM than in adenocarcinoma. Tissue Polypeptide Antigen (TPA) and Cyfra 21-1 are useful markers when tested in tissue or in the blood and can be used as prognostic marker or in monitoring the disease [51] . Chromosomal breakage, aneuploidy and translocations have been described in the genetic material of MM although no specific chromosomal aberrations have been characterized [52, 53] . Mutations in the tumour suppressor gene, p53, do not seem to be a requisite for malignant transformation of mesothelial cells [54] .
Diagnosis, staging and prognostic signs
Most patients present relatively late with symptoms since the onset of the MM is usually insidious. The most frequently reported complaints are localized pain (as a result of growth in the chest wall) and dyspnea due to the presence of a pleural effusion. Weight loss, coughing and fever are also present in a large proportion of patients. A typical feature of the tumour is obliteration of the thoracic cavity with encasement of the lung. Retraction of the involved chest side with diminished breath movements are observed in advanced cases. Mediastinal invasion can lead to dysphagia, superior vena caval syndrome or pericardial effusion. Electrocardiographic analysis can show arrhythmia's, nonspecific ST-T changes, atrial fibrillation or conducting abnormalities [55] . Bronchoscopic examination has not shown to be useful in MM and only reveals extrinsic compression of the airways.
Radiographic analysis with chest X-ray usually shows a one sided effusion and a diffuse thickening of the pleura. In advanced cases the thoracic cavity is reduced in size and the mediastinum can be shifted to the involved site [24] . CT scanning is very useful for determining the extent of the disease and evaluation of the diaphragm and mediastinal structures (large vessels, heart, lymph nodes and the esophagus) as shown in Figure la and b [56, 57] . The exact place of the MRI has yet to be defined but may lead to better insight in the extent of involvement in the chest wall and mediastinum (see Figure 2a and b) [58, 59] . In some cases the involve- Tumor involving all of the ipsilateral pleural surfaces with at least one of the following features:
• diffuse extension or multifocal masses of tumor in the chest wall, with or without local rib destruction; • direct transdiaphraagmatic extension of tumor in the peritoneum; • direct extension of tumor to the contralateral pleura;
• direct extension of tumor in one or more mediastinal organs; • direct extension of tumor into the spine; • tumor extending through to the internal surface of the pericardium with or without a pericardial effusion: or tumor involving the myocardium. ment of the diaphragm can best be investigated by laparoscopy [60] . The use of ultrasound is limited because of the limited penetration in the pleura, the occurrence of pleural fluid and the presence of the ribs to completely evaluate the extend of the tumour. Another method of investigation is the positron emission scanning (PET scan) which may enable differentiation between malignant and benign tissue (e.g., fibrosis) [61] . Gallium scanning has been reported to be helpful, but nonspecific, in monitoring asbestos exposed populations which have a high risk for the development of pleural disease [62] .
Thoracenthesis yields a serous or bloody exsudate which is often not diagnostic. Sometimes tumour cells are found (up to 38%) but exact determination of the type of MM can only be accomplished by histology [63, 64] . The diagnosis of MM is primarily made on thoracoscopic biopsy material with a sensitivity of 80% [63] and should preferably be checked by expert pathologists. Besides the evacuation of pleural fluid, the thoracoscopy is required for proper staging by inspection of the visceral and parietal pleura, the mediastinum and the diaphragm. Additionally a pleurodesis (with e.g., talc) can be performed to prevent the recurrence of a pleural exsudate. The use of a new staging system as advised by the International Mesothelioma Interest Group (IMIG) [65] reflects the difficulty in proper staging of this disease. Table 1 shows this (pathological) staging system. Although the disease is initially a localized process, micrometastases to the lymph nodes do occur and have a prognostic significance [44, 57, 66] . Optimal staging is required for selection of patients who could benefit from a aggressive local (multimodality) treatment and to allow comparison between different studies.
The different prognostic signs that have been identified in MM are presented in Table 2 . Like lung carcinoma, performance score, age at diagnosis and stage of disease are considered the most important prognostic signs although significance for these variables is not always observed. Epithelial tumours, age younger than 60, performance score 0-1 (ECOG) and stages I and II are good prognostic signs while sex, previous exposure to asbestos, smoking or weight loss do not seem to influence survival [74] . Tumour markers are often supportive in making the diagnosis but essentially have no diagnostic value. The cytokeratin markers like Tissue Polypeptide Antigen (TPA) and Cyfra 21-1 (measuring cytokeratin fragment 19) are increased in 50% of the cases at diagnosis and are useful in determination of tumour response to (chemo) therapy [51, 75] . The level of CEA is only moderately elevated in < 5% of the patients and is therefore used to exclude mesothelioma [76, 77] . Hyaluronic acid, a glycosaminoglycan, can be elevated in the epithelial form of MM since it occurs in rapidly growing connective tissue. Unfortunately it is not tumour specific but can be used to differentiate between adenocarcinoma and mesothelioma [78] . Analysis of the pH in pleural fluid in MM showed that a low pH value of < 7.3 was associated with a poor prognosis [79] .
Treatment
The treatment of MM has been disappointing so far regardless the type of treatment used. Monotherapy, like surgery and radiotherapy are considered effective in very localized disease only. Multimodality therapies incorporating surgery and another form of local adjuvant therapy (see below) are currently under investigation. Survival figures must always be interpreted with caution and be compared with the average survival of nine months with supportive care alone [80] .
Surgery
Surgical intervention in MM is often used for diagnosis and in some cases for therapy. When pleural effusion is abundant or rapidly recurrent and does not respond to conventional therapy a palliative decortication is sometimes indicated [81, 82] .
The most aggressive approach in the treatment of MM is an extrapleural pneumonectomy. Although mortality of the operation was initially high (20%-25%) the use of new techniques and improved peri-operative care has reduced this to 6%-15% [83, 84] . Table 3 summarizes results of some of the published series, which indicate survival rates ranging from 3% to 36% at three years. The studies are difficult to compare since patient selection and the use of additional therapies varies greatly and may have an influence on the survival figures. So far adjuvant chemo-and/or radiation therapy have not proved to be effective in preventing local recurrences. Patient numbers for adjuvant PDT are still too small to be able to evaluate whether this is more effective in controlling local disease.
Surgery with photodynamic therapy or intracavitary chemotherapy
Photodynamic therapy has been used by several investigators as an adjuvant treatment after surgical resection. Although the resection appears to be radical small tumour nests are usually left behind and require additional treatment. After injection of a photosensitiser, which is retained with some preference in the tumour cells and its vasculature, illumination of the chest cavity 4% 35% had local recurrence 5% local recurrence 83%
Phase I study, additional operation time 89 min Good local control, all developed distant metastases, additional illumination time < 2 hours 4 local and 2 distant failures, additional operation time 2.5-9.5 hours 2 postoperative death, 50% postoperative complications additional operation time 2 hours 1 local failure, additional illumination time 30-60 min
Abreviations: PI -pleurectomy; Br -brachytherapy; ERT -external radiotherapy; CT -chemotherapy; EPP -extra pleural pneumonectomy; PDT -photodynamic therapy; HPD -hematoporphyrin derivative; mTHPC -meta-TetraHydoxyPhenylChlorin; NA -not available.
with laser light of a specific wavelength leads to a photochemical reaction with oxygen. This will finally result in tumour destruction. Initial studies were performed with the photosensitizer Photofrin, which has a limited selectivity and the light required to excite the drug (630 nm) has a penetration depth of a few millimeters. The lack of high power lasers at the time these studies were carried out, combined with the relative inefficiency of this photosensitizer lead to very long illumination times and limited the use of PDT in the operating theater. Recently, new studies have been published showing that some of the above problems can be solved [66, 95] . Second generation photosensitizers with longer excitation wavelengths and higher singlet oxygen yield are now available. This together with the technological development of transportable high power lasers and an increased knowledge of light delivery and dosimetry have renewed the interest for this combination treatment. A summary of combined PDT/surgery treatments is presented in Table 3 .
Intracavitary chemotherapy is currently being used as adjuvant after surgical resection. High peak levels of cisplatin (up to 240 times higher) compared to blood levels can be obtained when the drug is given directly intra pleurally or intraperitoneally. Intraperitoneal mitomycin C has been tested in a number of cases but the results were inconclusive [98, 99] .
Radiotherapy
For 'curative' radiotherapy the target dose should be > 50 Gy but the dose that can safely be given is limited by normal tissue toxicity of the spinal cord, the heart and the oesophagus. Most reported studies have given a doses of 30 to 40 Gy to the hemithorax [100] . Higher doses of radiotherapy have been given by Eschwege [101] and Kutcher [102] but survival was not superior to control groups. Good palliation can, however, be achieved with radiation therapy for metastasis in needle or surgical tracts and for the palliation of pain and recurrent pleural fluid [100] . The combination of radiotherapy with chemotherapy has not lead to improved survival. Combination of surgery and brachy-therapy indicates some survival advantage for early disease [103] .
Chemotherapy
The limited number of patients with MM per institution hampers an objective evaluation of the different chemotherapeutic trials (single agent or combination treatment). This analysis is also difficult since patients with different tumour load, cell type, stage and performance are entered in these studies. Single agent chemotherapy has been evaluated extensively in small series of patients and only a few drugs showed responses of 15%-20% (see Table 4 ). New drugs like gemcitabine, vinorelbin, liposomal doxorubicin and topotecan have been or are currently being tested by larger groups like the EORTC. The most active drugs tested so far are mitomycin C [118] , doxorubicin [109] , cisplatin [107, 125] and highdose methotrexate [126] .
Combination therapy has been tested mostly with doxorubicin or mitomycin C but the overall results are comparable with the single drug alone (see Table 5 ). Further information on chemotherapeutic treatments are published by Krarup-Hansen [127] and by Ong [128] . The combination chemotherapy regimens indicate that only modest increases in response rate can be achieved but mean survival time is unchanged. For proper response evaluation it is important to note that the CT scan only provides an impression of the radiologic tumour response and does not inform about the biological response. We must, however, keep in mind that it is difficult to influence the mean survival time in a disease in which more than 70% of the patients do not respond to therapy and that statistical analysis between two treatment modalities are difficult to compare [137] .
RNase compounds acting as antibody against t-RNA of the endoplasmatic reticulum are possibly new treatment modalities in MM [142] .
Interferons have been used in MM for modulation of the immune response. Christmas et al. [143] used systemic recombinant a-interferon in a phase II study which gave a response rate of 15% (two PR/13 patients). For small pleural tumours (<5 mm nodules), intrapleural administration of recombinant a-interferon was found to be active [144] . In stage la patients four out of nine patients achieved a complete response and there was one partial response. Only one out of 10 patients with stage II disease achieved a partial response indicating that tumour response was related to tumour mass.
Preclinical investigations are ongoing to determine the usefulness of cytokines like IL-2, IL-12 and anti TGF-P in the modulation of the immune response. Although in mice models these cytokines appear to be of value, the time has not yet come to test these compounds in humans, because of their cost and toxicity profiles [145] [146] [147] .
Biological therapy
The use of altered (recombinant) adeno and herpes viruses as vectors to transfer suicide genes are currently being investigated in vivo animal models and phase I clinical studies [138, 139] . After the instillation of the viral vector in the pleural space a significant humoral and cellular immune response is generated. The antiviral agent ganciclovir is then given to obtain tumour cell kill. So far a dose dependent gene transfer has been observed. Further studies must evaluate its tumoricidal effect, whether distribution in the pleural space is adequate and the possible involvement of a bystander effect of this treatment [140, 141] . 
Conclusion
Malignant mesothelioma has gained more attention since its incidence is increasing despite the (relatively late) prohibition of the mining and processing of asbestos. Although some forms of asbestos are very carcinogenic, other, not yet fully identified, environmental factors may also lead to the development of MM. The use of an international staging system is important to properly select patients for experimental treatment and to allow comparing different studies. Single modality treatment (surgery, immuno or radiotherapy), seem to be useful for very small tumours. Although a standard treatment has not been identified so far but in selected patients, combined modality treatment has shown incidental interesting results. The new developments in combined modality and biological therapy will hopefully lead to better survival figures in this dismal disease.
